Charles E. Cooley

Array ( [id] => 11714920 [patent_doc_number] => 20170183412 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-06-29 [patent_title] => 'Human Antigen Binding Proteins That Bind To a Complex Comprising beta-Klotho and an FGF Receptor' [patent_app_type] => utility [patent_app_number] => 15/400800 [patent_app_country] => US [patent_app_date] => 2017-01-06 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 13 [patent_no_of_words] => 87359 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15400800 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 15963157 [patent_doc_number] => 20200165330 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-28 [patent_title] => HIGH-AFFINITY ANTI-VEGF ANTIBODY [patent_app_type] => utility [patent_app_number] => 16/067931 [patent_app_country] => US [patent_app_date] => 2017-01-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 16235 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 24 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16067931 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13837397 [patent_doc_number] => 20190022183 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-24 [patent_title] => A NOVEL LIQUID FORMULATION OF LONG-ACTING HUMAN GROWTH HORMONE CONJUGATE [patent_app_type] => utility [patent_app_number] => 16/066877 [patent_app_country] => US [patent_app_date] => 2016-12-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7735 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16066877 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589702 [patent_doc_number] => 20170114113 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'POLYPEPTIDES AS APELIN INHIBITORS AND USES THEREOF' [patent_app_type] => utility [patent_app_number] => 15/391893 [patent_app_country] => US [patent_app_date] => 2016-12-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 6627 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15391893 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11851687 [patent_doc_number] => 20170226178 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-10 [patent_title] => 'THERAPEUTIC USES OF MODIFIED RELAXIN POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/386347 [patent_app_country] => US [patent_app_date] => 2016-12-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 30 [patent_figures_cnt] => 30 [patent_no_of_words] => 123507 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15386347 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13733147 [patent_doc_number] => 20180371041 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-27 [patent_title] => FGF21 VARIANTS [patent_app_type] => utility [patent_app_number] => 15/776726 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 22039 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -30 [patent_words_short_claim] => 253 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15776726 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13606911 [patent_doc_number] => 20180355004 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-12-13 [patent_title] => HETERODIMERIC VASCULAR ENDOTHELIAL GROWTH FACTOR AND USE THEREOF [patent_app_type] => utility [patent_app_number] => 15/780734 [patent_app_country] => US [patent_app_date] => 2016-12-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 4704 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 47 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15780734 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14040793 [patent_doc_number] => 20190076503 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-14 [patent_title] => PHARMACEUTICAL COMPOSITION FOR PREVENTING AND TREATING CANCER OR CANCER METASTASIS, CONTAINING FSTL1 PROTEIN AS ACTIVE INGREDIENT [patent_app_type] => utility [patent_app_number] => 15/777497 [patent_app_country] => US [patent_app_date] => 2016-11-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 5455 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15777497 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 12254235 [patent_doc_number] => 09926371 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2018-03-27 [patent_title] => 'M-CSF specific monoclonal antibody and uses thereof' [patent_app_type] => utility [patent_app_number] => 15/347171 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 44 [patent_figures_cnt] => 45 [patent_no_of_words] => 49384 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 135 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15347171 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11962108 [patent_doc_number] => 20170266261 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-09-21 [patent_title] => 'PROTEIN THERAPY FOR TREATMENT OF RETINAL DISEASES' [patent_app_type] => utility [patent_app_number] => 15/346829 [patent_app_country] => US [patent_app_date] => 2016-11-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 65 [patent_figures_cnt] => 65 [patent_no_of_words] => 38563 [patent_no_of_claims] => 9 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15346829 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 16244857 [patent_doc_number] => 10744185 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-08-18 [patent_title] => Methods of using variants of FGF19 polypeptides for the treatment of pruritus [patent_app_type] => utility [patent_app_number] => 15/773120 [patent_app_country] => US [patent_app_date] => 2016-11-08 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 11 [patent_figures_cnt] => 11 [patent_no_of_words] => 58084 [patent_no_of_claims] => 52 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 43 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15773120 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13507771 [patent_doc_number] => 20180305428 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-25 [patent_title] => LONG-ACTING FGF21 FUSION PROTEINS AND PHARMACEUTICAL COMPOSITION COMPRISING SAME [patent_app_type] => utility [patent_app_number] => 15/768616 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10214 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -20 [patent_words_short_claim] => 229 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768616 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 17134818 [patent_doc_number] => 11136364 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => Dual function proteins comprising FGF21 mutant protein and pharmaceutical composition comprising same [patent_app_type] => utility [patent_app_number] => 15/768865 [patent_app_country] => US [patent_app_date] => 2016-10-28 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 24 [patent_figures_cnt] => 24 [patent_no_of_words] => 15822 [patent_no_of_claims] => 25 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 220 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15768865 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11589705 [patent_doc_number] => 20170114117 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-27 [patent_title] => 'COMPOUNDS THAT BIND MACROPHAGE MIGRATION INHIBITORY FACTOR' [patent_app_type] => utility [patent_app_number] => 15/331612 [patent_app_country] => US [patent_app_date] => 2016-10-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 10899 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15331612 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 14072309 [patent_doc_number] => 20190085042 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-03-21 [patent_title] => FUSION POLYPEPTIDE COMPRISING THE EXTRACELLULAR BINDING DOMAIN OF GROWTH HORMONE RECEPTOR [patent_app_type] => utility [patent_app_number] => 15/766899 [patent_app_country] => US [patent_app_date] => 2016-10-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 8241 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15766899 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11555195 [patent_doc_number] => 20170101442 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-04-13 [patent_title] => 'Peptide Ligands for Hepatic Stellate Cells' [patent_app_type] => utility [patent_app_number] => 15/288837 [patent_app_country] => US [patent_app_date] => 2016-10-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 23 [patent_figures_cnt] => 23 [patent_no_of_words] => 7851 [patent_no_of_claims] => 20 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15288837 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13763511 [patent_doc_number] => 10174090 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2019-01-08 [patent_title] => FGF21 protein with enhanced binding affinity for b-Klotho for the treatment of type II diabetes, obesity, and related metabolic disorders [patent_app_type] => utility [patent_app_number] => 15/283862 [patent_app_country] => US [patent_app_date] => 2016-10-03 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 18 [patent_no_of_words] => 40945 [patent_no_of_claims] => 32 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 30 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15283862 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11395190 [patent_doc_number] => 20170015724 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-01-19 [patent_title] => 'Growth Hormone Receptor Agonists' [patent_app_type] => utility [patent_app_number] => 15/283404 [patent_app_country] => US [patent_app_date] => 2016-10-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 10983 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15283404 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 13457863 [patent_doc_number] => 20180280474 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-10-04 [patent_title] => TREATMENT OF BILE ACID DISORDERS [patent_app_type] => utility [patent_app_number] => 15/765144 [patent_app_country] => US [patent_app_date] => 2016-09-30 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 18474 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 20 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15765144 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11866161 [patent_doc_number] => 20170233446 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2017-08-17 [patent_title] => 'METHODS AND COMPOSITIONS USING KLOTHO-FGF FUSION POLYPEPTIDES' [patent_app_type] => utility [patent_app_number] => 15/271198 [patent_app_country] => US [patent_app_date] => 2016-09-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 40 [patent_figures_cnt] => 40 [patent_no_of_words] => 28553 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15271198 [rel_patent_id] =>[rel_patent_doc_number] =>)